Can acetazolamide be used to treat diseases involving increased bone mineral density?

DOI: 10.5582/irdr.2016.01067 PMCID: PMC5116865 PMID: 27904825

Sclerosing bone dysplasias are a series of clinically and genetically heterogeneous diseases characterized by functional failure of the osteoclasts in  bone resorption, leading to an excessive amount of bone mineral density (BMD) which could have serious clinical consequences. We treated three children affected with seriously high levels of BMD with acetazolamide, with the intention of inducing metabolic acidosis, thus increasing bone resorption and reducing BMD. All our patients tolerated and followed the treatment well and the clinical response was satisfactory in all cases.

Autor: González-Rodríguez JD, Luis-Yanes MI, Inglés-Torres E, Arango-Sancho P, Cabrera-Sevilla JE, Duque-Fernández MR, Gil-Sánchez S,García-Nieto VM

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter